GentiBio Secures NIH Backing for Allogeneic Engineered Treg Therapy in Type 1 Diabetes

GentiBio, Inc. has received a USD 1.07 million NIH Phase II grant from the National Institute of Diabetes and Digestive and Kidney Diseases to advance an allogeneic, off-the-shelf engineered Treg therapy for newly diagnosed type 1 diabetes. q